Vol 12, No 1 (2021)
Case report
Published online: 2021-09-29

open access

Page views 3146
Article views/downloads 400
Get Citation

Connect on Social Media

Connect on Social Media

Ponatinib in treatment of chronic myeloid leukemia with T315I mutation

Klaudia Cieśluk1, Jarosław Piszcz1
Hematology in Clinical Practice 2021;12(1):33-35.

Abstract

Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation t(9;22)(q34;q11) which causes the formation of the Philadelphia chromosome (Ph). Therapeutic progress made in the last two decades and new-generation tyrosine kinase inhibitors (TKIs) introduction, signifi cantly increased patients’ prognosis. We present a case study of a Ph-positive CML patient with a point BCR/ABL1 mutation T315I treated with ponatinib.

Article available in PDF format

View PDF Download PDF file

References

  1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007; 370(9584): 342–350.
  2. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
  3. Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017; 12(2): 79–84.
  4. Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019; 10: 2040620719826444.
  5. https://www.ema.europa.eu/en/documents/product.



Hematology in Clinical Practice